[go: up one dir, main page]

HK1024182A1 - Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations - Google Patents

Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations

Info

Publication number
HK1024182A1
HK1024182A1 HK00103624A HK00103624A HK1024182A1 HK 1024182 A1 HK1024182 A1 HK 1024182A1 HK 00103624 A HK00103624 A HK 00103624A HK 00103624 A HK00103624 A HK 00103624A HK 1024182 A1 HK1024182 A1 HK 1024182A1
Authority
HK
Hong Kong
Prior art keywords
benzimidazols
stabilization
amino acid
acid
sensitive
Prior art date
Application number
HK00103624A
Other languages
English (en)
Inventor
Karin Klokkers
Marion Kutschera
Wilfried Fischer
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8226585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1024182(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of HK1024182A1 publication Critical patent/HK1024182A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891Coated capsules; Multilayered drug free capsule shells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK00103624A 1997-03-13 2000-06-16 Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations HK1024182A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97104200 1997-03-13
PCT/EP1998/001478 WO1998040069A2 (en) 1997-03-13 1998-03-13 Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations

Publications (1)

Publication Number Publication Date
HK1024182A1 true HK1024182A1 (en) 2000-10-05

Family

ID=8226585

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00103624A HK1024182A1 (en) 1997-03-13 2000-06-16 Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations

Country Status (24)

Country Link
US (1) US6248758B1 (cs)
JP (1) JP4608031B2 (cs)
KR (1) KR100563764B1 (cs)
CN (1) CN1113649C (cs)
AT (1) ATE209491T1 (cs)
AU (1) AU731186B2 (cs)
BR (1) BR9808581A (cs)
CA (1) CA2282513C (cs)
CZ (1) CZ291842B6 (cs)
DE (1) DE69802688T3 (cs)
DK (1) DK0991407T4 (cs)
ES (1) ES2167891T5 (cs)
HK (1) HK1024182A1 (cs)
HU (1) HU225587B1 (cs)
IL (1) IL131651A0 (cs)
NO (1) NO327212B1 (cs)
NZ (1) NZ337592A (cs)
PL (1) PL191570B1 (cs)
PT (1) PT991407E (cs)
SI (1) SI0991407T2 (cs)
SK (1) SK284811B6 (cs)
TR (1) TR199902233T2 (cs)
WO (1) WO1998040069A2 (cs)
ZA (1) ZA982155B (cs)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP4127740B2 (ja) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
PT1018340E (pt) * 1999-01-06 2003-12-31 Tecnimede Sociedade Tecnico Medicinal Sa Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
CN1322850C (zh) * 2000-06-02 2007-06-27 沈阳药科大学 盐酸尼卡地平粉针剂及其制备方法
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
JP2004513183A (ja) * 2000-11-14 2004-04-30 バイタル ヘルス サイエンシズ プロプライアタリー リミティド リン酸誘導体の複合体
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
JP4745608B2 (ja) * 2001-07-27 2011-08-10 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 電子伝達剤のリン酸誘導体を用いた皮膚治療
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
GB2379854B (en) * 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
BR0215102A (pt) * 2001-12-13 2004-11-03 Vital Health Sciences Pty Ltd Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
JP2005514443A (ja) * 2002-01-15 2005-05-19 アルタナ ファルマ アクチエンゲゼルシャフト パントプラゾール・シクロデキストリン包接錯体
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US7732474B2 (en) * 2002-08-02 2010-06-08 Ratiopharm, Gmbh Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ITMI20022549A1 (it) * 2002-12-02 2004-06-03 Actimex S R L Composizione quaternaria comprendente come sostanza attiva la propolis.
US20040109920A1 (en) * 2002-12-04 2004-06-10 Bioactives Llc Coated carotenoid cyclodextrin complexes
EP1589964B1 (en) * 2003-01-17 2011-11-23 Vital Health Sciences Pty Ltd. Compounds having anti-proliferative properties
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2005084678A1 (en) 2004-03-03 2005-09-15 Vital Health Sciences Pty Ltd Alkaloid formulations
KR20050105565A (ko) * 2004-04-30 2005-11-04 에스케이케미칼주식회사 저장안정성이 우수한 벤즈이미다졸 유도체 함유 포접복합체 및 이의 제조방법
WO2005112637A1 (en) * 2004-05-14 2005-12-01 Decode Chemistry, Inc. Formulations for non-parenteral use including hydrophobic cyclodextrins
US20060058276A1 (en) * 2004-07-15 2006-03-16 Oded Friedman Processes for the preparation and purification of rocuronium bromide
ATE494911T1 (de) * 2004-08-03 2011-01-15 Vital Health Sciences Pty Ltd Träger für die enterale verabreichung
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005008412A1 (de) * 2005-02-24 2006-09-07 Ratiopharm Gmbh Piperazinsalz des Omeprazols und dessen Enantiomere
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
NZ565049A (en) 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1973547A1 (en) * 2005-12-23 2008-10-01 Vital Health Sciences Pty Ltd. Compounds having cytokine modulating properties
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2873524C (en) 2006-05-04 2018-02-20 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US7840305B2 (en) 2006-06-28 2010-11-23 3M Innovative Properties Company Abrasive articles, CMP monitoring system and method
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20100009967A1 (en) * 2008-06-30 2010-01-14 Majid Mahjour Solid dosage formulations of telcagepant potassium
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR101791403B1 (ko) * 2008-08-15 2017-10-30 베링거 인겔하임 인터내셔날 게엠베하 Fab-관련 질환의 치료에 사용하기 위한 퓨린 유도체
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
WO2011120084A1 (en) 2010-03-30 2011-10-06 Phosphagenics Limited Transdermal delivery patch
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
CA2803504C (en) 2010-06-24 2022-08-30 Boehringer Ingelheim International Gmbh A combination for diabetes therapy comprising linagliptin and a long-acting insulin
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
JP5876150B2 (ja) 2011-07-15 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換キナゾリン、これらの調製及び医薬組成物中のこれらの使用
CN102584633B (zh) * 2011-12-16 2013-07-03 山东大学 一种赖氨酸α-氨基的苄氧羰基高效选择性保护方法及其产品
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN107847476A (zh) * 2015-07-13 2018-03-27 协和发酵生化株式会社 含高浓度精氨酸的片剂
WO2017096427A1 (en) 2015-12-09 2017-06-15 Phosphagenics Limited Pharmaceutical formulation
CN106924179B (zh) * 2015-12-29 2021-04-30 成都康弘药业集团股份有限公司 一种含有富马酸沃诺拉赞的液体制剂及其制备方法
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR101829685B1 (ko) * 2016-07-28 2018-02-19 씨제이헬스케어 주식회사 안정성 및 용해도가 개선된 주사용 조성물
KR101829705B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 안정성이 향상된 주사용 조성물
CA3045702A1 (en) 2016-12-21 2018-06-28 Phosphagenics Limited Phosphorylation process of complex alcohols
CN108324957B (zh) * 2018-04-20 2021-04-13 广州白云山医药集团股份有限公司白云山制药总厂 一种s-羧甲基-l-半胱氨酸包合物及其肠溶制剂组合物
CN116585283B (zh) * 2023-05-26 2024-11-22 桂林华信制药有限公司 兰索拉唑肠溶胶囊及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
DE3427786A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Inklusionskomplexe von benzimidazolderivaten mit cyclodextrinen, deren herstellung und arzneimittel
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
KR920008161B1 (ko) * 1990-02-19 1992-09-24 한미약품공업주식회사 오메프라졸 경구용 약제의 제조방법
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
TW224049B (cs) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
DE723436T1 (de) * 1994-07-08 1997-09-11 Astra Ab Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i)
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
JPH0948730A (ja) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole

Also Published As

Publication number Publication date
PT991407E (pt) 2002-05-31
DK0991407T4 (da) 2005-08-08
DK0991407T3 (da) 2002-03-25
CN1250372A (zh) 2000-04-12
TR199902233T2 (xx) 1999-12-21
NZ337592A (en) 2001-01-26
NO994409D0 (no) 1999-09-10
WO1998040069A3 (en) 1998-12-17
SI0991407T1 (en) 2002-04-30
ES2167891T3 (es) 2002-05-16
EP0991407B1 (en) 2001-11-28
KR20000076232A (ko) 2000-12-26
PL191570B1 (pl) 2006-06-30
HU225587B1 (en) 2007-03-28
ATE209491T1 (de) 2001-12-15
DE69802688T3 (de) 2006-01-26
IL131651A0 (en) 2001-01-28
HUP0002364A3 (en) 2001-12-28
SI0991407T2 (en) 2005-10-31
WO1998040069A2 (en) 1998-09-17
JP2001518083A (ja) 2001-10-09
DE69802688D1 (de) 2002-01-10
EP0991407B9 (en) 2002-11-13
ES2167891T5 (es) 2005-11-16
SK120999A3 (en) 2000-09-12
CA2282513C (en) 2007-09-18
PL335571A1 (en) 2000-05-08
AU731186B2 (en) 2001-03-29
EP0991407A2 (en) 2000-04-12
NO327212B1 (no) 2009-05-11
CA2282513A1 (en) 1998-09-17
US6248758B1 (en) 2001-06-19
KR100563764B1 (ko) 2006-03-24
JP4608031B2 (ja) 2011-01-05
NO994409L (no) 1999-10-21
CZ312899A3 (cs) 2000-02-16
SK284811B6 (sk) 2005-12-01
ZA982155B (en) 1998-12-01
BR9808581A (pt) 2000-05-30
DE69802688T2 (de) 2002-08-01
AU7207098A (en) 1998-09-29
HUP0002364A2 (hu) 2000-12-28
CN1113649C (zh) 2003-07-09
CZ291842B6 (cs) 2003-06-18

Similar Documents

Publication Publication Date Title
HK1024182A1 (en) Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
GB9409778D0 (en) Compositions
BG106030A (en) Pharmaceutical composition
MY129356A (en) Electrospun pharmaceutical compositions
CA2294783A1 (fr) Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
NZ501066A (en) Pharmaceutical formulations containing voriconazole and sulphobutylether beta-cyclodextrin
AU7962200A (en) Novel indole derivatives and drugs containing the same as the active ingredient
NO20006646D0 (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
HUP0001739A2 (hu) Gyógyászati hatóanyagok behatolását fokozó oldószerrendszert tartalmazó helyileg alkalmazott készítmények, valamint pufferolt oldószerrendszer alkalmazása
MXPA03005221A (es) Composicion farmaceutica de dronedarona para administracion parenteral.
AR012868A1 (es) COMPOSICIoN FARMACÉUTICA QUE COMPRENDE UN PÉPTIDO AGONISTA DE LHRH, UN ANTAGONISTA DE LHRH O UN PÉPTIDO DE GRF Y NICOTINAMIDA.
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
AU1650501A (en) 1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
TR200103151T2 (tr) Karboksipeptidaz U inhibitörü ile trombin inhibitörünü içeren farmasötik bir formülasyon.
RS50074B (sr) Farmaceutski preparat koji sadrži paracetamol i drotaverin
AU1556601A (en) 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
ES2130069A1 (es) Preparacion farmaceutica con liberacion retardada del producto activo.
ECSP993104A (es) Nueva formulacion oral

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170313